Type-2 Diabetes Market Size 2023-2028: Merck & Co, AstraZeneca, Novo Nordisk. Bristol-Myers Squibb, Eli Lilly

According to MarkNtel Advisors study the Global Type-2 Diabetes Market is projected to grow at a CAGR of around 8.0% during the forecast period, i.e., 2023-28.

“In case you missed it, we are currently revising our reports. Click on the below to get the most latest research data with forecast for years 2024 to 2030, including market size, industry trends, and competitive analysis. It wouldn't take long for the team to deliver the most recent version of the report.”    

Access Free Sample Report - https://www.marknteladvisors.com/query/request-sample/global-type-2-diabetes-market.html

Key Findings of the Study: Type-2 Diabetes market

Growth Opportunities: Inclusion of The New Therapeutic Compounds

The introduction of new medicinal substances with enhanced efficacy and safety into the type 2 diabetes market globally has created the potential for the creation of new treatments. Therapeutic treatments with a unique MoA are offered by drugs such DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, colesevelam, and bromocriptine QR. Additionally, they stop weight gain and lessen the chance of hypoglycemia. Despite the fact that not everyone should take these medications, they give medical professionals a number of alternatives for tailoring patient care and improving healthcare. The introduction of biosimilar pharmaceuticals is anticipated to increase at a quick rate over the anticipated period because of their low cost, strict product quality control standards, and straightforward production processes.

For more detailed information about the Type-2 Diabetes market report, click here – https://www.marknteladvisors.com/research-library/global-type-2-diabetes-market.html

Scope of the Report and Type-2 Diabetes Market Segmentation:

By Drug Type

• Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

• Alpha-glucosidase Inhibitors

• Biguanides

• Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

• Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2)

• Sulfonylureas

• Other (Thiazolidinediones, Meglitinides, Glitazones, etc.)

By Gender

• Male

• Female

Between the two, the Women segment held a significant market share in the Global Type-2 Diabetes market in 2022, owing to the alarming rise in the prevalence of type-2 diabetes among pregnant women.

By Age Group

• Upto 19 years

• 20 – 65 years

• Above 65 years

Type-2 Diabetes Market Competitive Landscape

• Merck & Co

• AstraZeneca

• Novo Nordisk

• Bristol-Myers Squibb

• Eli Lilly

• Sanofi

• Boehringer Ingelheim

• Pfizer

• Takeda

• Biocon

• Johnson & Johnson

Type-2 Diabetes Market Development:

• In August 2022, AstraZeneca's diabetes drug Farxiga exhibits significant reductions in hospitalization and death risks among patients with all types of heart failure.

• In June 2022, AstraZeneca’s Bydureon BCise, an exenatide 2 mg prolonged-release suspension for injection in a pre-filled pen, has been approved to include in the treatment of type-2 diabetes (T2D) in children and adolescents (10 years and above) in the European Union (EU).

Geographical Analysis:

By Region

• North America

• South America

• Europe

• Middle East & Africa

• Asia-Pacific

Here, North America captured a considerable market share in the Global Type-2 Diabetes market in 2022, with The US acquiring the majority market share in the region.

Note: If you require specific information not covered in the current report, we can provide it through customized option

Why choose Us?

MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others.

For Media Inquiries, Please Contact:

Call: +1 628 895 8081 | +91 120 4278433

Email: sales@marknteladvisors.com

Sales Office: 564 Prospect St, B9, New Haven, Connecticut, USA-06511

Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India